Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 4:35 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1873–1896 of 2,103 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Injectable saline Clear all

Conditions: Gender Dysphoria, Opioid Use, Pain, Postoperative
Interventions: Ropivacaine 0.2% Injectable Solution, Saline (0.9%); Drug · Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 65 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Familial Hypercholesterolemia - Heterozygous
Interventions: Inclisiran, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 6 Years to 11 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 9
States / cities: San Francisco, California • Washington D.C., District of Columbia • Boca Raton, Florida + 4 more

Conditions: Prediabetes, Obesity
Interventions: Exenatide, Saxagliptin, Exenatide extended-release (ER), Placebo; Drug · Other
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 30 Years to 70 Years
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Opioid Dependence, Pain, Addiction
Interventions: Placebo, Hydromorphone, Buprenorphine; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 55 Years
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Incisional Pain
Interventions: TAP Catheter and Infusion of Study Solution; Procedure
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: San Diego, California

Conditions: Peripheral Arterial Disease
Interventions: Granulocyte-Macrophage Stimulating Factor (GM-CSF), Placebo; Drug
Lead sponsor: Emory University; Other
Eligibility: 21 Years to 80 Years
Enrollment: 159 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Vaccines, Meningococcal Vaccines
Interventions: rLP2086 + MCV4 + Tdap, MCV4 + Tdap + saline, rLP2086 + saline; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 10 Years to 12 Years
Enrollment: 2,648 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2014
U.S. locations: 117
States / cities: Birmingham, Alabama • Daphne, Alabama • Chandler, Arizona + 73 more

Conditions: Post-traumatic Stress Disorder
Interventions: Stellate Ganglion Block, Sham Stellate Ganglion Block; Procedure
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 80 Years
Enrollment: 410 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 6
States / cities: Long Beach, California • Tampa, Florida • Minneapolis, Minnesota + 3 more

Conditions: Healthy
Interventions: Recombinant Human Prolactin; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2011
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Osteoarthritis, Knee
Interventions: Bone Marrow Derived MSCs, Corticosteroid, Bone Marrow Aspirate; Biological · Drug · Device
Lead sponsor: Next Generation Regenerative Medicine LLC; Network
Eligibility: 18 Years to 80 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 3
States / cities: Chesterfield, Missouri • Steubenville, Ohio • Salt Lake City, Utah

Conditions: Breast Reduction
Interventions: Bupivacaine Hydrochloride, Liposomal Bupivacaine; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 70 Years · Female only
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Cytomegalovirus Infection
Interventions: mRNA-1647, Placebo; Biological · Other
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 18 Years to 40 Years
Enrollment: 315 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 9
States / cities: Sacramento, California • Peoria, Illinois • Lenexa, Kansas + 5 more

Conditions: Facial Skin Texture, Facial Skin Pigmentation
Interventions: Autologous facial fat graft injection; Other
Lead sponsor: University of Pittsburgh; Other
Eligibility: 35 Years to 70 Years · Female only
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Atrial Fibrillation
Interventions: Stellate ganglion block, Bupivacaine, Placebo; Procedure · Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 60 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Post-operative Pain
Interventions: 15mL 0.25% bupivacaine, Genicular nerve block, Saline; Drug · Procedure
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 85 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Infections
Interventions: Normal saline pressurized irrigation, sub-q gentamicin; Procedure · Drug
Lead sponsor: Dallas VA Medical Center; Federal
Eligibility: 18 Years to 95 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Opioid Use, Surgical Recovery, Vaginal Hysterectomy, Prolapse Pelvic, Postoperative Pain
Interventions: Bupivacaine-epinephrine, Normal saline; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older · Female only
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Raleigh, North Carolina

Conditions: Healthy
Interventions: 5 mg/N6022, Placebo, 10mg/N6022, 20mg/N6022; Drug
Lead sponsor: Nivalis Therapeutics, Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Ebola Virus Infection
Interventions: TKM-100802 for Injection, Placebo; Drug
Lead sponsor: Arbutus Biopharma Corporation; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Brain Metastases
Interventions: 18F-Fluciclovine (Axumin) PET/CT; Diagnostic Test
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years to 99 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Muscle Spasticity
Interventions: Hyaluronidase, Placebo; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Wrinkle
Interventions: Restylane Silk, Saline, Optical Coherence Tomography; Drug · Device
Lead sponsor: Heidi Waldorf; Other
Eligibility: 25 Years to 55 Years · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: New York, New York

Conditions: Osteoarthritis: Joint Replacement Surgery
Interventions: CLARIX FLO, Saline; Other
Lead sponsor: BioTissue Holdings, Inc; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: Orange Park, Florida

Conditions: Rheumatoid Arthritis
Interventions: Olokizumab, Placebo; Drug
Lead sponsor: R-Pharm International, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 368 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 50
States / cities: Phoenix, Arizona • Hot Springs, Arkansas • Covina, California + 44 more

Search by objective public record fields.

The Effect of Pectoral Blocks on Perioperative Pain in Gender Affirmation Top Surgery

Study to Evaluate Efficacy and Safety of Inclisiran in Children With Heterozygous Familial Hypercholesterolemia

Effects of Antidiabetic Medications on the Postprandial State in Prediabetes

Study of the Treatment of Experimental Pain in Opioid Dependent Persons on Methadone or Buprenorphine Maintenance

Continuous Transversus Abdominis Plane Nerve Block for Postoperative Analgesia

Granulocyte-Macrophage Stimulating Factor in the Treatment of Peripheral Arterial Disease

A Clinical Trial to Study the Safety, Tolerance and Immunogenic Response to MCV4, Tdap and Bivalent rLP2086 Vaccine When Given at the Same Time to Children Between the Ages of 10 Through 12 Years of Age

Stellate Ganglion Block for PTSD

The Safety and Efficacy of Recombinant Human Prolactin

Mesenchymal Stem Cell Therapy for Knee Osteoarthritis

A Study of Liposomal Bupivacaine Versus 0.25% Bupivacaine Hydrochloride Post Breast Reduction

Dose-Finding Trial to Evaluate the Safety and Immunogenicity of Cytomegalovirus (CMV) Vaccine mRNA-1647 in Healthy Adults

Autologous Facial Fat Grafting Study

A Study of Stellate Ganglion Block for Prevention of Atrial Fibrillation

Genicular Nerve Block for Total Knee Arthroplasty

Effectiveness for Interventions to Minimize Surgical Site Infections

Paracervical Injection and Opioid Use After Vaginal Hysterectomy for Prolapse

A Safety Study Evaluating N6022 in Multiple-Ascending Doses in Healthy Subjects

Safety, Tolerability and Pharmacokinetic First in Human (FIH) Study for Intravenous (IV) TKM-100802

Feasibility of 18F-Fluciclovine PET/CT to Identify Brain Metastasis

Peripheral Modulation of Muscle Stiffness and Spasticity

Restylane Silk for Treatment of Chest Wrinkles

Amniotic Umbilical Cord Particulate During Total Knee Arthroplasty

Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo, in Subjects With Rheumatoid Arthritis (RA) Who Were Taking an Existing Medication Called a Tumour Necrosis Factor Alpha Inhibitor But Had Active Disease